Verve Therapeutics Statistics
Total Valuation
OmniAb has a market cap or net worth of $234.88 million. The enterprise value is $212.54 million.
Important Dates
The next confirmed earnings date is Wednesday, August 6, 2025, after market close.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OmniAb has 122.34 million shares outstanding. The number of shares has increased by 3.50% in one year.
| Current Share Class | 122.34M |
| Shares Outstanding | 122.34M |
| Shares Change (YoY) | +3.50% |
| Shares Change (QoQ) | +0.79% |
| Owned by Insiders (%) | 9.60% |
| Owned by Institutions (%) | 46.62% |
| Float | 87.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.40 |
| Forward PS | 8.97 |
| PB Ratio | 0.85 |
| P/TBV Ratio | 4.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.70, with a Debt / Equity ratio of 0.08.
| Current Ratio | 4.70 |
| Quick Ratio | 4.39 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -21.32% and return on invested capital (ROIC) is -13.95%.
| Return on Equity (ROE) | -21.32% |
| Return on Assets (ROA) | -13.18% |
| Return on Invested Capital (ROIC) | -13.95% |
| Return on Capital Employed (ROCE) | -23.56% |
| Revenue Per Employee | $234,596 |
| Profits Per Employee | -$537,474 |
| Employee Count | 114 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -6.87M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.92% in the last 52 weeks. The beta is 0.92, so OmniAb's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | -59.92% |
| 50-Day Moving Average | 1.74 |
| 200-Day Moving Average | 2.82 |
| Relative Strength Index (RSI) | 48.45 |
| Average Volume (20 Days) | 596,879 |
Short Selling Information
The latest short interest is 8.19 million, so 6.69% of the outstanding shares have been sold short.
| Short Interest | 8.19M |
| Short Previous Month | 8.34M |
| Short % of Shares Out | 6.69% |
| Short % of Float | 9.37% |
| Short Ratio (days to cover) | 12.17 |
Income Statement
In the last 12 months, OmniAb had revenue of $26.74 million and -$61.27 million in losses. Loss per share was -$0.59.
| Revenue | 26.74M |
| Gross Profit | 26.74M |
| Operating Income | -69.44M |
| Pretax Income | -76.18M |
| Net Income | -61.27M |
| EBITDA | -49.96M |
| EBIT | -69.44M |
| Loss Per Share | -$0.59 |
Full Income StatementBalance Sheet
The company has $43.60 million in cash and $22.48 million in debt, giving a net cash position of $21.12 million or $0.17 per share.
| Cash & Cash Equivalents | 43.60M |
| Total Debt | 22.48M |
| Net Cash | 21.12M |
| Net Cash Per Share | $0.17 |
| Equity (Book Value) | 273.52M |
| Book Value Per Share | 2.24 |
| Working Capital | 42.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.50 million and capital expenditures -$1.16 million, giving a free cash flow of -$39.66 million.
| Operating Cash Flow | -38.50M |
| Capital Expenditures | -1.16M |
| Free Cash Flow | -39.66M |
| FCF Per Share | -$0.32 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -259.65% and -229.11%.
| Gross Margin | 100.00% |
| Operating Margin | -259.65% |
| Pretax Margin | -254.78% |
| Profit Margin | -229.11% |
| EBITDA Margin | -186.82% |
| EBIT Margin | -259.65% |
| FCF Margin | n/a |
Dividends & Yields
OmniAb does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.50% |
| Shareholder Yield | -3.50% |
| Earnings Yield | -26.22% |
| FCF Yield | -16.97% |
Analyst Forecast
The average price target for OmniAb is $7.00, which is 264.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 264.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 30.31% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OmniAb has an Altman Z-Score of 7.77 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.77 |
| Piotroski F-Score | 3 |
